compound introduction
LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist. In Vivo At 3 mg/kg, LAS101057 is active in preventing Acetyl-β-methylcholine-induced AHR, and at 10 mg/kg it inhibits AHR to Acetyl-β-methylcholine to a level virtually equal to that seen with Hexadecadrol at 1 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
